- Home
- KROS vs EU Comparison
KROS vs EU Comparison
Compare KROS & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- EU
- Stock Information
- Founded
- KROS 2015
- EU 2009
- Country
- KROS United States
- EU United States
- Employees
- KROS N/A
- EU N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- EU Other Metals and Minerals
- Sector
- KROS Health Care
- EU Basic Materials
- Exchange
- KROS Nasdaq
- EU Nasdaq
- Market Cap
- KROS 558.9M
- EU N/A
- IPO Year
- KROS 2020
- EU N/A
- Fundamental
- Price
- KROS $13.37
- EU $2.79
- Analyst Decision
- KROS Buy
- EU Strong Buy
- Analyst Count
- KROS 13
- EU 1
- Target Price
- KROS $20.63
- EU $2.75
- AVG Volume (30 Days)
- KROS 637.6K
- EU 3.6M
- Earning Date
- KROS 08-06-2025
- EU 08-13-2025
- Dividend Yield
- KROS N/A
- EU N/A
- EPS Growth
- KROS N/A
- EU N/A
- EPS
- KROS 0.11
- EU N/A
- Revenue
- KROS $214,713,000.00
- EU $46,179,000.00
- Revenue This Year
- KROS $5,006.76
- EU $27.46
- Revenue Next Year
- KROS N/A
- EU $140.12
- P/E Ratio
- KROS $123.16
- EU N/A
- Revenue Growth
- KROS 91657.70
- EU N/A
- 52 Week Low
- KROS $9.12
- EU $1.01
- 52 Week High
- KROS $72.37
- EU $4.44
- Technical
- Relative Strength Index (RSI)
- KROS 42.27
- EU 67.84
- Support Level
- KROS $13.25
- EU $2.25
- Resistance Level
- KROS $13.99
- EU $2.93
- Average True Range (ATR)
- KROS 0.36
- EU 0.18
- MACD
- KROS -0.06
- EU 0.03
- Stochastic Oscillator
- KROS 20.75
- EU 81.32
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.